As more biosimilars continue to be approved across the world, it is helpful to compare the applicable regimes across major jurisdictions. We have collaborated with Brian Coggio of Fish & Richardson, and Mary Foord-Weston and Camilla Balleny of Carpmaels & Ransford to prepare the chart below comparing relevant considerations for biosimilars in Canada, the US, and Europe, including regulatory pathways, data protection and patent linkage.

Footnote

1 Currently 53 approved for use in Europe, 2 refused, 8 withdrawn

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.